ClinicalTrials.gg
RecruitingNCT06804161SGLT2-HYPEUpdated Dec 22, 2025

SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension

A Phase 3 interventional study of SGLT2 and Placebo in Atrial Hypertension, sponsored by Prof. Dr. med. Ingo Eitel. Recruiting at 1 site in Germany. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Prof. Dr. med. Ingo Eitel · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,000
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 282 studies in Hypertension with a site in Germany — 29 open to participants now, 46 under way, 11 of them phase 3. Hypertension · Germany.

Planned enrollment
8th of 250
3,000 · median 200
Started
2025
with 14 others
Phase 3
122 of 282
6 open now
Primary completion
2032-05
later than 45 of 45 live
Registered
264th of 282
by date

Among the 282 studies in Hypertension with a site in Germany, this one is the 8th largest by planned enrollment of the 250 interventional ones that give a count, is one of 15 that started in 2025, is one of 122 in phase 3, reaches primary completion later than 45 of the 45 other live ones, and was the 264th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

29 of the 282 studies in Hypertension with a site in Germany are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 282 studies in Hypertension with a site in Germany, or all of them as a file.
02

Study summary

Hypertension (HTN) is a leading cause of cardiovascular disease (CVD). Despite existing therapies, patients with HTN still face substantial risks, due to pre-existing and ongoing end-organ damage due, in part, to inadequate blood pressure (BP) control. SGLT2 inhibitors (SGLT2i) are recommended for both type-2 diabetes and heart failure to reduce morbidity and mortality. SGLT2i reduce BP and might also improve outcomes for HTN by reducing end-organ damage through diverse other actions. However, confirmation that SGLT2i are clinically useful for the management of HTN is required to change guidelines and clinical practice.

03

Conditions studied

  • Atrial Hypertension

Browse trials for

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Age ≥60 years
  2. Systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg in two measurements on different days for newly diagnosed hypertension, or through one measurement at the screening visit for patients with an existing diagnosis of hypertension.
  3. A history of at least one CV event (myocardial infarction* or stroke*; stable angina or clinical evidence of coronary heart disease; peripheral arterial disease; )

or

The presence of at least one cardiovascular risk factor (current smoking of more than one cigarette per day during at least 1 year; LDL-cholesterol > 4,0 mmol/l, Age ≥ 75 years, ESC HeartScore > 15%, > 32 kg/m2)

*excluding patients with myocardial infarction or stroke within preceding 3 months

Exclusion Criteria:- Known secondary cause of hypertension

  • Myocardial infarction or stroke within the previous 3 months
  • Symptomatic heart failure (including HFrEF, HFmEF, HFpEF)
  • History of Diabetes mellitus
  • History of ketoacidosis
  • Hepatic impairment ( [AST] or alanine transaminase [ALT] >3x the [ULN])
  • \<25 mL/min/1.73 m2 (CKD-EPICr 2021 formula) at Visit 1
  • Receiving therapy with an SGLT2i within 8 weeks prior to randomization or previous intolerance to an SGLT2i
  • Participation in another clinical study with an product during the last month prior to enrolment
  • Known allergy or to SGLT2i
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial
  • Any medical condition - outside the renal and CV disease area - with a of less than 2 years based on investigator's clinical judgement
  • Active requiring treatment at the time of visit 1 (with the exception of successfully treated basal cell or treated squamous cell carcinoma)
  • Inability to give
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Care provider)
Enrollment
3,000 participants (estimated)

Study arms

  • Experimental
    SGLT2 Arm

    Drug: SGLT2

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time until first occurrence of

    Time frame: 7 Years

Other outcomes

  1. Safety endpoints

    * AE (general) * AE leading to treatment discontinuation * SAE * AE of special interest (AESI): including volume depletion, hypotension, metabolic acidosis and ketoacidosis

    Time frame: 7 Years

07

Study locations

1 of 1 sites recruiting
  • Universität zu Lübeck
    Lübeck, Schleswig-Holstein 23538, Germany
    Recruiting
    • Ingo Eitel, Prof. Dr. med. · Contact
    • Thomas Stiermaier, Dr.med · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for May 2032, 77 months after the start.

Of 46 non-industry phase 3 interventional studies under Hypertension, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 77 months is above that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2025
First posted
Feb 3, 2025
StartActual
Dec 10, 2025
Primary completionEst.
May 30, 2032
CompletionEst.
May 30, 2032
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06804161
Lead sponsor
Prof. Dr. med. Ingo Eitel
Responsible party
Prof. Dr. med. Ingo Eitel (Head of department of medical clinic II, University of Luebeck) — Sponsor-investigator
First posted
Feb 3, 2025
Start date
Dec 10, 2025
Primary completion
May 30, 2032 (estimated)
Completion
May 30, 2032 (estimated)
Last update
Dec 22, 2025

Study contacts

Ingo Eitel, Prof. Dr.
Contact
cvro@uksh.de
045150044542
Elias Rawish, Dr.
Contact
Ingo Eitel, Prof. Dr.
principal investigator · Universitätsklinikum Schleswig-Holstein - Campus Lübeck

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium/Glucose Cotransporter 2

Start the discussion